A Unified Front

READDI accelerates progress through global partnerships.

As we work to mitigate the risk of future pandemics, science leads our efforts, innovation accelerates them and global partnerships scale the best of what we create together.

Leveraging the best of academia, government and industry

The threat of emerging viruses is bigger than any one company, government or institution. Stopping viral pandemics requires a unified global collaboration across disciplines, working toward the common goal of a safer future.


RTI International is an independent, nonprofit research institute dedicated to improving the human condition and addressing the world’s most critical problems with science-based solutions in pursuit of a better future. RTI awarded UNC-Chapel Hill $5 million in the Forethought Challenge, advancing READDI research.

The National Institute of Allergy and Infectious Disease (NIAID) funded the $65 million READDI Antiviral Drug Discovery Center (READDI-AC) at UNC-Chapel Hill, one of nine Antiviral Drug Discovery (AViDD) Centers focused on innovative, multidisciplinary research to develop candidate antivirals.

The NC Collaboratory has a significant COVID-19 research portfolio supported with $29 million in funding from the North Carolina General Assembly. The Collaboratory has supported multiple READDI projects at UNC-Chapel Hill with over $3.5 million of funding.

In February of 2022, the North Carolina General Assembly approved $18 million of COVID-19 relief funding to UNC-Chapel Hill to support a portfolio of 11 innovative READDI projects focused on developing novel COVID-19 treatments at UNC-Chapel Hill.


The Structural Genomics Consortium is driving a new scientific and drug discovery ecosystem by focusing on less well-studied areas of the human genome. A pioneer of open science, the consortium — a network of academic and industry scientists — catalyzes research in new areas of human biology and drug discovery by focusing on genetics. And the SGC shares all research with the scientific community — no strings attached. The SGC has partnerships with nine global pharmaceutical companies and collaborations with scientists at hundreds of universities globally.

SAS is a global leader in analytics, with 82,000 customers in 145 countries. SAS has supported public health and drug development for decades and remains the gold standard for clinical trial submission in the U.S., providing the data analysis for medicines that have helped countless patients. Born in academia 45 years ago, SAS partners with READDI to apply the most advanced technologies to accelerate drug discovery and support global health efforts to get ahead of the next pandemic.

DNDi has provided READDI with a proven model, given its own approach to nonprofit drug research. Founded by Médecins Sans Frontières, the World Health Organization and five international research institutions, DNDi discovers, develops and delivers new treatments for neglected patients around the world that are affordable and patient-friendly — and that have already saved millions of lives.

The emergence of another deadly virus is a matter of when, not if.

We must be ready, not reactive.